Prima BioMed is a clinical‐stage biotechnology company specializing in the development of immuno‐oncology therapies. Founded in 2001 and headquartered in Sydney, Australia, the company applies its proprietary LAG-3 platform to modulate the immune response against cancer. This approach leverages both agonist and antagonist strategies to enhance antigen presentation and stimulate T-cell activity, aiming to overcome the limitations of existing checkpoint inhibitors.
The company’s lead asset, eftilagimod alpha (IMP321), is a first‐in‐class soluble LAG-3 fusion protein designed to activate antigen‐presenting cells. Eftilagimod alpha is currently being evaluated in combination with pembrolizumab in Phase II trials for patients with metastatic breast cancer, building on earlier studies in melanoma and non‐small cell lung cancer. Prima BioMed’s pipeline also includes next‐generation LAG-3 antagonists that are in preclinical and early clinical development for solid tumors.
Prima BioMed has pursued a global clinical development strategy, conducting trials across key oncology centers in North America, Europe and Australia. The company maintains research partnerships with leading academic institutions and collaborates with clinical investigators to advance its immunotherapy candidates. Prima BioMed’s intellectual property portfolio includes multiple patents covering LAG-3 mechanisms, therapeutic compositions and manufacturing processes.
The company’s leadership team combines biotech industry veterans with deep expertise in oncology drug development and regulatory affairs. Executive Chairman Paul Hopper co‐founded Prima BioMed and brings extensive experience in life‐science funding and strategy, while Chief Executive Officer Marc Voigt oversees clinical operations and corporate development. Together, they guide Prima BioMed’s efforts to bring novel immunotherapies to patients with unmet medical needs.
AI Generated. May Contain Errors.
